Ceropram

Escitalopram

Method of action: Antidepressant, Blocking The Reuptake Of Serotonin, Psychoanaleptics

Treatment option: Agoraphobia, Generalized Anxiety Disorder, Depression, Obsessive Compulsive Disorder, Obsessive Compulsive Personality Disorder, Panic, Anxiety&Panic Attacks, Panic Attacks And Panic Disorder, Phobia, Phobia,Social

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ceropram

Property	Description
Active Ingredient	Escitalopram
Form	Oral tablet, Oral solution
Pharmacological Class	Selective Serotonin Reuptake Inhibitor (SSRI)
General Purpose	Mood stabilization and emotional balance
Origin	Synthetic compound

What Type of Medicine is Ceropram?

Ceropram is a synthetic, psychotropic pharmaceutical agent classified under the highly focused group of Selective Serotonin Reuptake Inhibitors (SSRIs). This classification indicates the medicine's primary action is dedicated to modulating neurochemistry in the central nervous system, and it is available exclusively as a prescription medicine. As an SSRI, its mechanism is designed for high specificity, differentiating it from older-generation antidepressants that commonly affected multiple neurotransmitters. Ceropram is recognized as a single-component product featuring Escitalopram, an active ingredient characterized by its high selectivity.

Escitalopram: Core Composition and General Purpose

The active ingredient in Ceropram is Escitalopram (INN), typically supplied as the oxalate salt, which is administered via the oral route in either a film-coated tablet or an oral solution form. The availability of the oral solution is a distinguishing feature, making it suitable for patients who may require dosage titration or have difficulty swallowing tablets. Escitalopram is chemically unique because it is the purified (S)-enantiomer of citalopram, which is the component associated with the drug’s pharmacological activity.

The fundamental physiological action is to slow the reabsorption of the neurotransmitter serotonin by binding to the Serotonin Transporter (SERT) protein. This targeted action enhances the availability of serotonin, a key chemical involved in regulating mood. The overall, general purpose of this potentiation of serotonergic activity is to assist individuals in achieving and maintaining emotional balance and stability. This medicine is typically recognized for its utility in situations requiring the management of significant mood changes and persistent, excessive worry.

Regulatory References

MedlinePlus Escitalopram Information

What side effects are possible with Ceropram?

The official safety profile of Ceropram (escitalopram) is defined by categories of adverse reactions and specific regulatory warnings documented by health authorities, such as the FDA and EMA. Adverse reactions are classified by frequency, with Nausea and Headache generally listed as Very Common occurrences (ge 1/10).

Adverse Reaction Classifications

Classification	Examples of Documented Effects (System-Organ Class)
Common (ge 1/100 to <1/10)	Insomnia, Somnolence, Diarrhea, Dry mouth (Gastrointestinal/Nervous System)
	Ejaculation disorder, Decreased libido (Reproductive/Psychiatric)
Uncommon (ge 1/1,000 to <1/100)	Abnormal bleeding (Hemorrhage), Tachycardia (Vascular/Cardiac)
Rare (ge 1/10,000 to <1/1,000)	Serotonin Syndrome, Anaphylactic reaction (Systemic/Psychiatric)

Serious Safety Considerations

The most critical safety constraints include a Boxed Warning regarding the risk of Suicidal Thoughts and Behaviors, particularly in children, adolescents, and young adults (up to age 24), which is heightened during the initial few months of therapy or at times of dose changes. Other documented serious risks include Serotonin Syndrome, QTc Interval Prolongation (a heart rhythm abnormality), and Hyponatremia (low sodium levels in the blood). Risk is noted to be higher for hyponatremia within the first few weeks of starting treatment.

Specific Population Safety

Special safety considerations are explicitly stated for certain patient groups. Older adults may have an increased susceptibility to hyponatremia, and generally recommended maximum dosages are often cited for this population and for patients with hepatic impairment. Use during the later stages of pregnancy may increase the risk for poor adaptation symptoms in the neonate. The concomitant use of escitalopram with MAOIs or Pimozide is officially contraindicated due to the potential for serious adverse consequences.

Overdose and Emergency Response

Overdose and when to seek help

Overdose with this medication, referred to in regulatory documents as Citalopram, is primarily associated with cardiac and neurological toxicity. The documented presentations include seizures, coma (loss of consciousness), agitation, confusion, and cardiovascular events.

The most serious physiological manifestation is dose-dependent QTc interval prolongation, an abnormal change in the heart's electrical activity. This can lead to potentially fatal abnormal heart rhythms, such as Torsade de Pointes and ventricular tachycardia, and sudden death. High doses, particularly those greater than 40 mg per day, are strongly associated with this cardiac risk, leading to regulatory dose restrictions. Patients over 60 years old and those with hepatic impairment or specific heart conditions (e.g., congenital long QT syndrome, congestive heart failure) are considered to be at higher risk for these serious outcomes.

In case of suspected overdose or if you experience severe symptoms like chest pain, dizziness, fainting, seizures, fever, severe muscle stiffness, or fast/irregular heartbeat, you must seek emergency medical treatment immediately or call the poison control helpline. These symptoms may also indicate Serotonin Syndrome, a serious condition documented to occur with overdose. Immediate medical evaluation is required if you observe signs of collapse, difficulty breathing, or cannot be awakened.

Therapeutic Uses of Ceropram

Ceropram (escitalopram) is applied across domains where additional symptomatic support is needed. This medication provides support that helps ease the overall symptom burden in situations where patients experience symptoms that interfere with daily functioning and cause distress.

Easing Persistent Low Mood and Major Depression

This domain is used in contexts marked by increased discomfort or tension associated with Major Depressive Disorder (MDD), addressing symptom clusters that may become intense or disruptive, such as prolonged sadness and the loss of pleasure or interest (anhedonia). It may be part of symptomatic management in acute episodes, and assists with supporting functional stability during long-term use. The conditions in which Ceropram is considered relevant include Major Depressive Disorder, Generalized Anxiety Disorder, Panic Disorder, and Obsessive-Compulsive Disorder.

“The medication is relevant when supportive symptom management is appropriate, helping patients cope more steadily with symptom fluctuations.”

Managing Chronic Worry and Anxiety Disorders

Ceropram is applied across domains where additional symptomatic support is needed for conditions like Generalized Anxiety Disorder (GAD) and Panic Disorder. It is relevant for managing symptoms that interfere with daily comfort, including excessive worry, mental tension, and sudden, intense fear episodes. When symptoms become temporarily overwhelming, this medication supports the patient during difficult episodes and contributes to easing the overall symptom load.

Quick Fact: Supports Management of Excessive Worry

Supportive Care for Obsessive-Compulsive Patterns

This medication is considered relevant in conditions characterized by periods of heightened symptoms, such as Obsessive-Compulsive Disorder (OCD). Ceropram is applied in addressing symptom clusters that may become intense or disruptive, including intrusive thoughts and associated compulsive behaviors. In scenarios where additional management of discomfort is required, the medication provides supportive relief when symptoms interfere with routine activities, which may assist with maintaining a sense of stability when symptoms are more noticeable.

Eligibility and Restrictions for Use

Official Regulatory Eligibility for Ceropram

Ceropram (Escitalopram) use is strictly governed by regulatory classifications that define eligibility, conditional use, and absolute prohibition based on patient populations and pre-existing conditions.

Eligibility Scope	Status as per Official Labeling
Absolute Contraindications	Prohibited for patients with a known hypersensitivity to escitalopram, those taking Monoamine Oxidase Inhibitors (MAOIs), concurrent pimozide, or those with a history of QT-interval prolongation or concurrent use of other QT-prolonging medicines.
Age-Group Eligibility	Approved for adults (18+), adolescents (12-17 years) for MDD, and pediatric patients (7+ years) for GAD. Use is not established below these age thresholds.
Conditional Use Populations	Caution is required in older adults, patients with reduced hepatic function, severe renal impairment, a history of seizures, mania/hypomania, or angle-closure glaucoma.
Pregnancy and Lactation	Not Recommended. Use during pregnancy is conditional on a risk-benefit assessment, and is generally not recommended while breastfeeding.

The regulatory profile mandates careful screening, ensuring that the medicine is reserved for populations where safety and effectiveness have been established, and strictly excluding those facing documented contraindications.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Ceropram (Escitalopram) emphasizes restrictions based on both pharmacodynamic and pharmacokinetic interactions documented in government labeling.

Contraindicated Combinations and Timing Rules

Co-administration is strictly prohibited (contraindicated) with all Monoamine Oxidase Inhibitors (MAOIs), including non-selective, irreversible MAOIs, Linezolid, and Intravenous Methylene Blue. This restriction is due to the documented risk of severe Serotonin Syndrome. A mandatory washout period of at least 14 days is required when switching between Ceropram and an MAOI. Additionally, co-administration is forbidden with Pimozide and other medicinal products that are officially known to prolong the QTc interval, citing cardiac safety concerns.

Pharmacokinetic and Exposure Effects

Escitalopram's metabolism involves CYP450 enzymes, primarily CYP2C19 and CYP3A4. Inhibitors of these enzymes, such as Omeprazole (a CYP2C19 inhibitor), may cause a documented increase in escitalopram plasma concentration (exposure). Ceropram itself acts as a moderate CYP2D6 inhibitor, which may lead to increased exposure of co-administered medicines metabolized by CYP2D6 (e.g., certain tricyclic antidepressants).

Mechanism of Action

How Ceropram Works

Ceropram is a compound that functions as a Selective Serotonin Reuptake Inhibitor (SSRI). Its mechanism of action begins with its ability to bind selectively and with high affinity to the Serotonin Transporter (SERT) protein located on the presynaptic neuronal membrane.

This binding action competitively inhibits the reuptake of the neurotransmitter serotonin (5-HT) back into the presynaptic neuron from the synaptic cleft. The immediate consequence of this inhibition is an increase in the concentration of 5-HT, leading to prolonged stimulation of postsynaptic 5-HT receptors and subsequent modulation of serotonergic pathway activity.

Over a longer duration, this sustained change in synaptic serotonin levels initiates a mechanistic cascade known as neuroadaptation. This cascade involves downstream neurotrophic changes, including the alteration of neuronal receptor density and signaling efficiency. These cellular and molecular adjustments within targeted neural circuits lead to altered systemic physiological outcomes.

Dosage and Administration Information

Administration and General Usage

Ceropram (escitalopram) is administered via the oral route as either a film-coated tablet or an oral solution (1 mg/mL concentration). The medication is designed for once-daily intake, which can be completed at any time of day, morning or evening, and may be taken with or without food.

Dosing and Adjustment Protocol

The established starting quantity for adults with Major Depressive Disorder or Generalized Anxiety Disorder is 10 mg once daily. The maximum dose for adult use is 20 mg once daily. When a dose increase is implemented, it typically occurs after a minimum of one week at the previous dosage, following a structured titration schedule. For the convenience of adjustment, certain higher-strength tablets are scored for dividing the dose.

Population-Specific Constraints

A lower daily dosage ceiling is established for certain patient groups. The dose often utilized for older adults (over 65 years) is 10 mg once daily. This same 10 mg maximum applies to individuals with known reduced hepatic function or those identified as CYP2C19 poor metabolizers.

Procedural Duration and Discontinuation

Treatment follows a protocol that includes an initial phase and subsequent continuation, which is typically sustained for at least six months following symptomatic resolution to maintain stability. Discontinuing the medicine requires a gradual dose reduction process (tapering), which is generally carried out over a period of at least one to two weeks, rather than an abrupt stop.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Early Research and Findings

Initial research has explored the properties of Compound X, a compound derived from botanical sources. Studies have explored whether the compound influences mobility and pain in people with mild-to-moderate osteoarthritis (OA). The findings from this early phase were generally limited and preliminary.

In-vitro investigations examined the compound's impact on inflammation markers.

Clinical Study Findings (Phase II/III Trials)

Osteoarthritis (OA)

A pooled analysis of three Phase II trials reported on the use of Compound X in adults with mild-to-moderate OA over a 12-week period. The primary outcome was the change in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain subscale. Findings were mixed across the studies, with two of the three trials reported a numerically higher change in the Compound X group compared to placebo.

One study of 150 participants reported that a reduction in swelling was observed by investigators in the Compound X group, and this observation continued through the trial duration.
Further research is needed to determine the clinical significance of these findings.

Rheumatoid Arthritis (RA)

Evidence regarding the use of Compound X for treating rheumatoid arthritis (RA) remains limited. A single pilot study with 40 participants examined the compound as an add-on therapy to existing disease-modifying anti-rheumatic drugs (DMARDs).

The study evaluated whether the compound could influence disease activity, as measured by the Disease Activity Score 28 (DAS28).
The trial reported no statistically significant difference in the primary endpoint compared to placebo plus DMARDs.

Pharmacokinetic and Dosing Studies

Studies investigated the optimal formulation to maximize the absorption of Compound X.

The combination of Compound X and Compound Z was used in all subsequent Phase III trials.
This dosage was examined in studies exploring absorption and bioavailability.
The studies administered doses in the lower range.

Frequently Asked Questions (FAQ)

Common questions about Ceropram (FAQ)

Q: What is Ceropram primarily used for?

According to official product information, escitalopram is indicated for the acute and maintenance treatment of Major Depressive Disorder (MDD) in adults and adolescents. It is also approved for the acute treatment of Generalized Anxiety Disorder (GAD) in adults.

Q: How quickly does Ceropram usually start working?

The full benefits of the medication may not be felt immediately. Based on patient information from authoritative sources, it may take approximately one month or longer of treatment before a person begins to feel an effect.

Q: What should I do if I miss a dose of Ceropram?

Regulatory patient guidance describes the protocol for a missed dose as taking it as soon as possible, or skipping it if it is almost time for the next dose to avoid doubling up. This guidance is informational and does not replace the instructions given by a prescriber.

Q: Can Ceropram be taken indefinitely, or only for a short time?

Clinical trials have demonstrated the benefit of maintenance (long-term) treatment for Major Depressive Disorder. For Generalized Anxiety Disorder (GAD), which is described as a chronic condition, the official product information states that the long-term usefulness of the drug is subject to periodic re-evaluation by the prescriber.

Q: Does Ceropram cause weight gain?

Clinical trial summaries indicate that patients using escitalopram may experience significant changes in weight and appetite. These changes can include either an increase or a decrease in body weight.

Q: What is the difference between Ceropram and Citalopram (or a similar common drug)?

Ceropram (escitalopram) is described in chemical terms as the purified S-enantiomer. This S-enantiomer is the specific component responsible for the majority of the pharmacological activity of the related drug citalopram.

Q: What is the risk of dependence or addiction with Ceropram?

The official prescribing information requires a gradual dose reduction (tapering) when discontinuing treatment to avoid potential discontinuation symptoms. This required tapering is a consideration related to physiological dependence.

Q: Can Ceropram make anxiety worse initially?

Warnings in the prescribing information note that some patients may experience a worsening of existing symptoms, including agitation, irritability, or other behavioral changes. This is primarily noted when starting treatment or following a dose change.

Q: How long after stopping Ceropram will it be completely out of my system?

The elimination half-life of escitalopram is approximately 30 hours after multiple dosing. Full clearance of the drug and its active metabolites from the body is generally considered to take about five half-lives.

Q: What is Serotonin Syndrome and how is it related to Ceropram?

Serotonin Syndrome is a serious adverse reaction reported with SSRIs like escitalopram, and is primarily caused by excessively high serotonin levels. Signs may include confusion, agitation, high body temperature, sweating, a rapid heart rate, and severe muscle rigidity.

Q: Are there any warnings about driving or operating machinery while on Ceropram?

The official warning indicates that caution is advised due to the potential for the medication to interfere with cognitive and motor performance. This is a standard precaution mentioned in the prescribing information.

Q: Is it okay to switch from another antidepressant to Ceropram?

Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is strictly prohibited. Regulatory documents mandate a washout period of at least 14 days when switching between escitalopram and an MAOI.

Q: Can Ceropram be taken if I have a heart condition?

Escitalopram is associated with a mild, dose-dependent prolongation of the QTc interval, which is a measure of heart rhythm. For this reason, the prescribing information states that the use of escitalopram is contraindicated for individuals with congenital long QT syndrome or other pre-existing QTc prolongation.

Q: What should I do if I accidentally take too much Ceropram?

Overdose symptoms, as described in regulatory documents, may include severe drowsiness, coma, dizziness, tremors, and a rapid heartbeat (tachycardia). The regulatory documents note that overdose requires immediate emergency medical attention.

Q: Does Ceropram affect appetite?

Clinical trial summaries for patients using escitalopram to treat Major Depressive Disorder have reported significant changes in appetite.

Q: Are there different brand names or generics for Ceropram?

Escitalopram is the generic name for the active ingredient. The medication is sold under various brand names, including Lexapro.

Q: How is Ceropram eliminated from the body?

The medication is metabolized primarily in the liver by specific enzymes (mainly CYP2C19) and eliminated from the body through both the liver and the kidneys. The major portion of the dose is excreted as metabolites in the urine.

Q: Are there specific tests I need before starting Ceropram?

The official prescribing information includes a precaution to assess patients for a history of bipolar disorder (mania/hypomania) before starting treatment. Additionally, warnings related to QTc prolongation and hyponatremia require clinical monitoring.

Q: Are there any known issues with taking Ceropram and having surgery?

Warnings in the official labeling state that use with substances that interfere with blood clotting is associated with an increased risk of bleeding. Caution is also advised due to the drug's potential for QTc interval prolongation, which is a consideration during medical procedures.

Q: Does the dose of Ceropram need to be adjusted for kidney issues?

Official product information states that no dosage adjustment is needed for patients with mild or moderate kidney impairment. However, severe kidney impairment is listed as a condition requiring caution.

How should Ceropram be stored and disposed of?

How to Store and Dispose of Ceropram

All storage and disposal requirements for Ceropram (escitalopram) are defined by regulatory documents to ensure product stability and safety.

Storage Requirements

Ceropram tablets and oral solution must be stored at Controlled Room Temperature, defined as 20^circ to 25 C (68^circ to 77 F), with permitted excursions up to 30 C (86 F). The medicine must be kept from freezing and protected from heat, moisture, and direct light. The container must be kept closed tightly to maintain integrity. A mandatory safety requirement is to store the product out of the reach of children.

Disposal Instructions

Unused or expired Ceropram should be discarded using a drug take-back program or a prepaid mail-back envelope as the preferred method. If these are not available, the medicine must be removed from its original container, mixed with an undesirable substance (e.g., dirt or coffee grounds), sealed in a bag, and then placed in the household trash. Disposal must always be in accordance with local and federal regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.